Over the weekend, the U.S. government announced first-ever negotiated prices for prescription drugs for ten drugs covered under Medicare Part D that will go into effect beginning January 1, 2026.
The negotiated prices are expected to save an estimated $6 billion in net covered prescription drug costs.
The price of Bristol Myers Squibb Co’s (NYSE:BMY) blood thinner Eliquis has been negotiated to $231.
Eli Lilly And Co’s (NYSE:LLY) diabetes treatment, Jardiance, is priced at $197, down 66%.
Johnson & Johnson’s (NYSE:JNJ) Xarelto (blood thinner), Stelara (psoriasis, arthritis, ulcerative colitis, Crohn’s disease), Imbruvica (blood cancer) could be available at $197, $4,695, and $9,319, respectively people enrolled in Medicare prescription drug coverage.
Merck & Co Inc’s (NYSE:MRK) blood pressure drug, Januvia, is priced at $113.
AstraZeneca Plc’s ...
